• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxter wins CE Mark for PrisMax continuous renal replacement system, TherMax blood warmer

Baxter wins CE Mark for PrisMax continuous renal replacement system, TherMax blood warmer

October 29, 2018 By Fink Densford

Baxter

Baxter (NYSE:BAX) said today that it won CE Mark approval in the European Union for its PrisMax continuous renal replacement system and TherMax blood warmer.

The newly cleared PrisMax system is the company’s next-gen renal replacement and organ support therapy tech, and is intended to supply a range of extracorporeal therapies to remove waste products, excess fluids and inflammatory mediators or helping manage acute kidney injury and to aid in sepsis management.

The TherMax blood warmer is intended to be used alongside the PrisMax system to maintain blood temperature as it is purified outside the body. The TherMax system uses a bi-directional connection with the PrisMax system to automatically adjust heating to prescribed blood temperatures.

“Baxter has been a leader in continuous renal replacement therapy technology for more than 20 years. We’ve built on this expertise to bring to market the most advanced technology currently available that directly addresses what clinicians have said they need to better treat patients: simplicity, efficiency and accuracy. The PrisMax system is foundational to accomplishing our shared vision to help transform care for critically ill patients and establish best-in-class treatments for a variety of organ support therapies,” Baxter acute therapies biz GM Reaz Rasul said in a press release.

Approval came based on a pilot study of the PrisMax system, which reported that the tech “delivered significant improvements in areas that impact efficiency and ease of use, including the time needed for bag changes, the number of information and malfunction alarms, how often the blood pump stops, filter life and machine downtime,” the company said.

Results from the trial were published in the journal Blood Purification.

“Our assessment of the PrisMax system across seven ICUs in six countries concluded that the device features several important enhancements that contribute to safety, efficiency and user friendliness. The launch of PrisMax is a big step forward for clinicians’ abilities to treat patients in the ICU more effectively,” lead study author Dr. Marcus Broman of Lund, Sweden’s Skåne University Hospital said in a prepared statement.

Baxter said that it intends to launch the system in more than 19 countries across Europe, with first releases in Denmark, France, Italy and Sweden.

Earlier this month, Baxter said that it inked a collaborative deal with the Mayo Clinic to develop a new renal care center of excellence in the US.

Filed Under: Blood Management, Featured, Regulatory/Compliance Tagged With: Baxter

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy